Abstract
Retinoic acid receptor-related orphan nuclear receptor gamma t (RORγt or RORC2) is a key transcription factor for the differentiation of naïve proinflammatory CD4(+) T cells and the production of T helper-17 (TH17) cells. Inhibiting RORγt activity is thought to be beneficial in targeting a variety of inflammatory and autoimmune disorders, however current candidates remain to be validated in the clinic. Recently Vitae Pharmaceuticals successfully finished its Phase 1 single ascending dose clinical study with their proprietary RORγt inverse agonist VTP-43742. On the basis of the reported promising results, Vitae Pharmaceuticals could currently be considered as having the leading clinical candidate in the RORγt inverse agonist category. This prompts the interest on the exact chemical structure of their clinical candidate. The first relevant patent application (WO2014179564) from Vitae Pharmaceuticals describes RORγt inverse agonists with a 5,6-dihydro-4H-pyrrolo[3,4-d]thiazole core, while in the second and latest patent application (WO2015116904) this element has changed towards a 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine core. By combining information from Vitae's patent applications and trustworthy online information, the potential ...Continue Reading
References
Aug 10, 2000·Organic Letters·J F MarcouxP J Reider
Nov 30, 2006·Pharmacological Reviews·Pierre GermainVincent Laudet
Apr 18, 2008·Advances in Developmental Biology·Anton M Jetten, Joung Hyuck Joo
Apr 22, 2009·Nuclear Receptor Signaling·Anton M Jetten
Nov 6, 2009·Molecular Pharmacology·Naresh KumarPatrick R Griffin
Jan 31, 2012·Chemistry & Biology·Thomas P BurrisPatrick R Griffin
Oct 2, 2012·Nature Reviews. Drug Discovery·Pierre Miossec, Jay K Kolls
Oct 19, 2012·Journal of Medicinal Chemistry·Li DiBo Feng
Feb 8, 2014·Journal of Medicinal Chemistry·Benjamin P Fauber, Steven Magnuson
Jul 16, 2014·Bioorganic & Medicinal Chemistry Letters·Benjamin P FauberHarvey Wong
Oct 13, 2014·Bioorganic & Medicinal Chemistry Letters·Christian GegeThomas Hoffmann
Dec 17, 2014·Journal of Medicinal Chemistry·Zoran Rankovic
Dec 17, 2014·Acta Pharmacologica Sinica·Yan ZhangYong Xu
Jun 7, 2015·Bioorganic & Medicinal Chemistry Letters·Benjamin P FauberHarvey Wong
Jun 11, 2015·Journal of Medicinal Chemistry·Benjamin P FauberHarvey Wong
Jul 15, 2015·Expert Opinion on Therapeutic Patents·Christian Gege
Jul 21, 2015·ACS Medicinal Chemistry Letters·Yonghui WangXichen Lin
Citations
Aug 21, 2016·Bioorganic & Medicinal Chemistry Letters·Patrick CyrJames J Crawford
Sep 16, 2016·Expert Opinion on Therapeutic Patents·Sarah M BronnerJames J Crawford
Nov 18, 2016·Expert Opinion on Therapeutic Patents·Christian Gege
Jun 8, 2017·ChemMedChem·Joerg KallenSamuel Hintermann
Jan 19, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Patrizia FaschingJohannes Fessler
Jun 24, 2018·Chemistry & Biodiversity·Moustafa T Gabr, Mohammed S Abdel-Raziq
Oct 30, 2019·ChemMedChem·Ayumu SatoSatoshi Yamamoto
Dec 6, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nannan SunWei Fu
Aug 4, 2019·The Journal of Pharmacology and Experimental Therapeutics·Stephen GauldPhilippe Masson
Dec 3, 2016·ChemMedChem·Samuel HintermannDavid Orain
Feb 26, 2019·Medicinal Chemistry·Christelle DoebelinTheodore M Kamenecka
Aug 7, 2019·Annual Review of Pharmacology and Toxicology·Anton M Jetten, Donald N Cook
Jul 6, 2019·Mediators of Inflammation·Carmen Rodríguez-CerdeiraJosé Luís González-Cespón
Jul 2, 2021·Expert Opinion on Drug Discovery·Christian Gege
Mar 7, 2018·Journal of Medicinal Chemistry·Mitsunori KonoSatoshi Yamamoto
Jul 11, 2018·Journal of Medicinal Chemistry·David A CarcacheSamuel Hintermann
Aug 11, 2018·Journal of Medicinal Chemistry·Frank NarjesThomas G Hansson
Nov 2, 2021·Journal of Medicinal Chemistry·Lei ChenZhi-Xin Liao
Mar 24, 2018·Current Opinion in Toxicology·Anton M JettenHong Soon Kang